Ka hoʻohālikelike ʻana o ʻelua mau ala ʻike no ka ʻike ʻana i ka SARS-CoV-2 receptor binding domain IgG antibody ma ke ʻano he surrogate marker no ka loiloi ʻana i nā antibodies neutralizing i nā mea maʻi COVID-19

Int J Infect Dis.Iune 20, 2021: S1201-9712(21)00520-8.doi: 10.1016/j.ijid.2021.06.031.Ma ka pūnaewele ma mua o ka paʻi ʻana.
Ka hope: He mea nui ka neutralizing antibodies (NAbs) i mea e pale ai i ka maʻi hou ʻana me COVID-19.Ua hoʻohālikelike mākou i ʻelua mau hoʻokolohua pili i ka NAb, ʻo ia hoʻi ka hoʻāʻo hemagglutination (HAT) a me ka hoʻāʻo neutralization virus pani (sVNT).
Nā Hana: Ua hoʻohālikelikeʻia ka kiko'ī o ka HAT me ka sVNT, a ua loiloiʻia ka naʻau a me ka lōʻihi o nā antibodies i nā maʻi me nā maʻi likeʻole i loko o kahi hui o 71 mau maʻi ma 4 a 6 mau wiki a me 13 a 16 wiki.ʻO ka loiloi kinetic o nā maʻi me nā maʻi koʻikoʻi o nā ʻano koʻikoʻi i hana ʻia i nā pule mua, ʻelua a me ke kolu.
Nā hualoaʻa: ʻO ka kikoʻī o HAT he> 99%, a ua like ka naʻau me ka sVNT, akā haʻahaʻa ma mua o ka sVNT.Hoʻopili maikaʻi ʻia ka pae o HAT me ka pae o sVNT (Spearman's r = 0.78, p<0.0001).Ke hoʻohālikelike ʻia me nā poʻe maʻi me ka maʻi ʻeha, ʻoi aku ka nui o nā titers HAT i nā poʻe maʻi me ka maʻi haʻahaʻa a koʻikoʻi.ʻO 6/7 nā maʻi maʻi maʻi i loaʻa ka titer o> 1: 640 i ka pule ʻelua o ka hoʻomaka ʻana, aʻo 5/31 wale nō nā maʻi maʻi haʻahaʻa i loaʻa ka titer o> 1: 160 i ka pule ʻelua o ka hoʻomaka ʻana.
Ka hopena: ʻOiai ʻo HAT he ala maʻalahi a maʻalahi loa ia e ʻike ai, kūpono ia ma ke ʻano he hōʻailona o NAb ma nā wahi ʻilihune waiwai.